Heart damage and the role of ultrasonic research in the COVID-19 pandemic

Павлюкова, Е. Н.; Скидан, В. И.; Россейкин, Е. В.; Нарциссова, Г. П.; Карпов, Р. С.

doi:10.29001/2073-8552-2021-36-1-38-48

Cited by 3 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…О функции ПЖ можно судить также по показателям FAC RV, амплитуде TAPSE и скорости его движения (S') [22]. Среднее значение FAC RV у пациентов нашего исследования находилось в пределах нормы, как и в исследовании отечественных коллег [21].…”

unclassified

Echocardiographic characteristics of COVID-19 pneumonia survivors three months after hospital discharge

et al. 2021

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is an infectious disease that affects almost all organs and systems. The main target is the respiratory system, but cardiovascular involvement is also common. Today, it is relevant to study the effect of complicated COVID-19 course on the patient’s cardiovascular system after hospital discharge — in particular, echocardiographic parameters.Aim. To study the echocardiographic parameters of patients with COVID-19 pneumonia 3 months after discharge from the hospital.Material and methods. The study included 106 patients with documented COVID-19 pneumonia. Patients underwent a comprehensive examination during hospitalization and 3 months ± 2 weeks after hospital discharge. The mean age of participants was 47±16 years (from 19 to 84 years), while 49% were women.Results. Three months after discharge, the average body mass index of the subjects was 28,2±5,7 kg/m2. Obesity was noted in 37,1%, cardiovascular diseases — in 52%. According to echocardiography, the prevalence of right ventricular (RV) dilatation was 2,9%, a decrease in tricuspid annular plane systolic excursion (TAPSE) — 9,5%, grade ≥2 tricuspid regurgitation — 1,9%, pulmonary hypertension (pulmonary artery systolic pressure >36 mm Hg) — 3,8%. The mean value of RV global longitudinal myocardial strain (GLMS RV) and global longitudinal myocardial strain (GLES RV) was 19,6±4,5 and 20,6±4,6, respectively. We found moderate correlations between GLMS RV and blood flow time through the left ventricular outflow tract (OT) (r=-0,436), through the mitral valve (r=-0,390; both p<0,0001) and through the RVOT (r=-0,348; р=0,004), with cardiac index (CI) (r=0,316; p=0,009), as well as between GLES RV and blood flow time through the LVOT (r=-0,411; p<0,0001) and RVOT (r=-0,300; p=0,005), and with CI (r=0,302; p=0,004). At the same time, the correlation of GLES RV with RV fractional area change (FAC) was weak (r=-0,283; p=0,007), while there was no correlation with the TAPSE. In addition, correlation of GLMS RV with these parameters were not defined.Conclusion. Three months after COVID-19 pneumonia, RV strain parameters were shown to have stronger relationships with time characteristics of flows in LVOT and RVOT, as well as with CI, than with such generally accepted characteristics of RV function as FAC and TAPSE.

show abstract

unclassified

Echocardiographic characteristics of COVID-19 pneumonia survivors three months after hospital discharge

et al. 2021

View full text Add to dashboard Cite

show abstract

Heart injury in COVID-19: immediate and long-term follow-up

2021

View full text Add to dashboard Cite

The article presents a review of bibliographic data on risk factors and mechanisms of the damage to the heart tissues in a new coronavirus infection. The direct viral-associated injury, as well as the influence of the components of the cytokine storm are analyzed. Myocarditis, cardiac arrhythmias are considered. In addition, the first results of long-term follow-up observations of patients who underwent COVID-19 were summarized, and the change in arterial stiffness was assessed.

show abstract

Cardiovascular complications of the coronavirus disease (COVID-19)

2022

View full text Add to dashboard Cite

A new coronavirus infection (COVID-19), which has spread widely in the human population in the past few years, is often complicated by a damage to the cardiovascular system, central nervous system, gastrointestinal tract, and respiratory system organs. The review describes the features of the clinical course and treatment of SARS-CoV-2 infection, which can lead to the development of cardiac complications both in the early and long-term periods. It is assumed that there are three main causes for the development of such complications (the affinity of the virus to endothelial proteins, the damage to blood vessels and the heart as a result of the immune response of the body and the toxic effects of drugs used to treat infection). Among the pathogenic mechanisms of the course of a new coronavirus infection that can lead to the development of cardiovascular complications, the following can be distinguished: manifestations of systemic vasculitis, coagulopathy, thrombosis, the phenomenon of “cytokine storm”, the direct cytotoxic damage to the myocardium, metabolic disorders, imbalance of the ionic composition of the blood, hypoxia and its consequences. The most common complications include myocarditis with arrhythmia (sinus tachycardia, bradycardia, atrial fibrillation and flutter, QTc prolongation, sudden cardiac death), cardiomyopathy (biventricular, isolated dysfunction of the right or left ventricle), cardiogenic shock, coagulopathy, thromboembolism (including strokes), vasculitis. Following recovery from COVID-19, many patients retain (or develop) the symptoms caused by the heart damage: a pain in the region of the heart, palpitations, appearance or aggravation of chronic heart failure, decompensation of hypertension, acute coronary syndrome. The main proposed directions for minimizing the risk of developing cardiac complications in COVID-19 patients include ECG monitoring (assessment of the QT interval, rhythm, conduction and repolarization), echocardiography in patients at risk, 24-hour ECG recording in patients who report palpitations. In addition, it is recommended to adjust the dosages of cardiotoxic drugs and to be cautious when prescribing anticoagulant therapy.

show abstract

Heart damage and the role of ultrasonic research in the COVID-19 pandemic

Cited by 3 publications

References 57 publications

Echocardiographic characteristics of COVID-19 pneumonia survivors three months after hospital discharge

Echocardiographic characteristics of COVID-19 pneumonia survivors three months after hospital discharge

Heart injury in COVID-19: immediate and long-term follow-up

Cardiovascular complications of the coronavirus disease (COVID-19)

Contact Info

Product

Resources

About